Tata India Pharma & Healthcare Fund
Tata Mutual Fund · Sectoral/Thematic · Direct plan, growth option
NAV (₹), 1 Oct 2026
38.0577
1-day change
-0.64%
1Y return
7.9%
3Y CAGR
18.3%
5Y CAGR
14.0%
Max drawdown, 5Y
−16.8%
NAV history month-end NAV, ₹ · 29 Dec 2015 to 1 Oct 2026
Returns vs Sectoral/Thematic median (253 schemes) and “Healthcare & pharma” median (19)
| Period | Scheme | Category median | Healthcare & pharma median |
|---|---|---|---|
| 1 month | -4.3% | -5.4% | -3.1% |
| 3 months | -0.1% | -2.8% | 3.0% |
| 6 months | 15.2% | 8.9% | 21.7% |
| Year to date | 7.6% | -2.0% | 17.3% |
| 1 year | 7.9% | 1.4% | 17.5% |
| 3 years (CAGR) | 18.3% | 13.0% | 20.8% |
| 5 years (CAGR) | 14.0% | 12.0% | 15.3% |
| 7 years (CAGR) | 22.3% | 17.0% | 24.9% |
| 10 years (CAGR) | 14.7% | 14.6% | 14.7% |
| Since first NAV (CAGR) | 13.2% | – | – |
“Healthcare & pharma” is MFIC's grouping of Sectoral/Thematic schemes by the theme or index in their names, not an AMFI category.
Rolling returns every business-day start date
| Measure | Scheme | Category median |
|---|---|---|
| 1Y rolling median | 9.0% | 11.8% |
| 3Y rolling median | 21.2% | 17.5% |
| 3Y rolling worst | -3.4% | 3.0% |
| 3Y periods positive | 91% | 100% |
| 3Y periods ahead of benchmark | 70% | 84% |
| 5Y rolling median | 16.7% | 15.6% |
| 5Y rolling worst | 9.3% | 1.8% |
| 5Y periods ahead of benchmark | 84% | 91% |
Benchmark: Nifty 500 (proxy: Motilal Oswal Nifty 500 Index Fund, price return).
Risk 36 months, monthly returns, Rf 6.5%
| Measure | Scheme | Category median |
|---|---|---|
| Standard deviation (ann.) | 16.5% | 16.7% |
| Sharpe ratio | 0.80 | 0.42 |
| Sortino ratio | 1.33 | 0.63 |
| Beta | 0.79 | 0.96 |
| Alpha (ann.) | 10.5% | 3.7% |
| Upside capture | 112.51 | 106.94 |
| Downside capture | 67.24 | 95.17 |
Drawdowns peak-to-trough falls in NAV
| Measure | Scheme | Category median |
|---|---|---|
| Maximum drawdown, full history | −19.8% | −23.1% |
| Maximum drawdown, last 10Y | −18.5% | −38.3% |
| Maximum drawdown, last 5Y | −16.8% | −22.3% |
| Current drawdown | −5.2% | −8.3% |
| Recovery time of worst fall | 375 days | – |
Longer histories include more crises, so compare the 5Y and 10Y figures across schemes of different ages.
Direct or Regular for this scheme?
The Regular plan's expense ratio is 2.37% a year and the Direct plan's 1.07%, a gap of 1.30%; over the last 3 years the Direct plan returned 1.72 percentage points a year more. On a ₹25,000 monthly SIP for 20 years (illustration at 12% a year before costs) the gap adds up to about ₹28,95,698.
With the Regular plan, that cost pays a distributor to help you plan, choose and review funds, and stay invested when markets fall. Whether it is worth it depends on how much of that you will do yourself.
TER: AMFI TER disclosure. Returns: AMFI NAVs. Illustration, not a guaranteed saving or return.
Recent disclosure changes last 120 days, as disclosed via AMFI
- 25 Sep 2026: TER increased from 1.06% to 1.07% (AMFI TER disclosure)
- 18 Sep 2026: TER reduced from 1.07% to 1.06% (AMFI TER disclosure)
- 10 Sep 2026: TER increased from 1.06% to 1.07% (AMFI TER disclosure)
- 8 Sep 2026: TER reduced from 1.07% to 1.06% (AMFI TER disclosure)
- 4 Sep 2026: TER increased from 1.06% to 1.07% (AMFI TER disclosure)
Fund managers and scheme facts Scheme Summary Document via AMFI
| Fund manager | Role | Managing since |
|---|---|---|
| Rajat Srivastava | Primary | 16 Sep 2024 |
Objective: The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns.
Stated asset allocation: Equity & equity related instruments of companies in the Pharma & Healthcare Sectors^ 80% - 100%, Other Equity/Equity related instruments 0% - 20%, Money Market Instruments, other liquid instruments**, gold and/or silver instruments/ETF, InvITs as permitted by SEBI 0% - 20%. The scheme may invest in another scheme under the same asset management company or any other mutual fund without charging any fees, provided that aggregate inter-scheme investment made by all schemes under the same management or in schemes under the management of any other asset management company shall not exceed 5% of the net asset value of the mutual fund. Such investments shall be made in the schemes which ar…
Benchmark (tier 1): BSE Healthcare TRI
Exit load: 0.25% of NAV if redeemed /switched out before 30 days from the date of allotment.
Minimum application: ₹5,000
Allotment date: 28 Dec 2015
Documents: Scheme Information Document · Scheme Summary Document. Read the scheme documents before investing.
Cost, size and riskometer as disclosed to AMFI
| Measure | Scheme | Category median |
|---|---|---|
| Expense ratio (TER), Direct plan | 1.07% | 1.15% |
| AUM, whole scheme (₹ crore) | n/a | 1,272 |
| Riskometer | n/a | – |
TER: AMFI, TER of MF Schemes. AUM and riskometer: AMFI, Fund Performance, 30 Sep 2026.
Official benchmark and category consistency
| Measure | Scheme | Benchmark / category |
|---|---|---|
| Month-ends above category median (3Y CAGR) | 68% | 53% median |
| Month-ends in category top quartile (3Y) | 49% | 24% median |
| 7Y rolling CAGR, median (monthly windows) | 20.2% | 15.2% median |
Category consistency: last 10 years of month-ends, Sectoral/Thematic Direct plans; how it is calculated.
Calendar-year returns NAV change from 31 Dec to 31 Dec
| Year | Scheme | Nifty 500 proxy | Difference |
|---|---|---|---|
| 2026 YTD | 7.6% | -7.8% | +15.4% |
| 2025 | -3.5% | 7.7% | −11.1% |
| 2024 | 42.5% | 15.6% | +26.8% |
| 2023 | 38.6% | 26.5% | +12.1% |
| 2022 | -6.6% | 3.8% | −10.4% |
| 2021 | 20.9% | 30.6% | −9.7% |
| 2020 | 66.9% | 17.2% | +49.7% |
| 2019 | 7.2% | n/a | – |
| 2018 | -0.8% | n/a | – |
| 2017 | 6.4% | n/a | – |
Benchmark proxy: Motilal Oswal Nifty 500 Index Fund (Direct plan NAV, price return), which carries its own costs. The first year starts from the first 31 December in the scheme's history.
Monthly SIP of ₹10,000 first business day of each month, ending 1 Oct 2026
| Period | Invested | Value | XIRR |
|---|---|---|---|
| 1 year | ₹1,20,000 | ₹1,26,435 | 10.1% |
| 3 years | ₹3,60,000 | ₹4,24,699 | 11.0% |
| 5 years | ₹6,00,000 | ₹9,08,034 | 16.6% |
| 10 years | ₹12,00,000 | ₹30,98,272 | 18.0% |
Uses this plan's NAVs; ignores stamp duty, exit loads and taxes. One historical path only — the interactive SIP analyzer shows outcomes across every start date.
Scheme facts
AMC: Tata Mutual Fund
Category: Sectoral/Thematic
Plan / option: Direct · Growth
AMFI scheme code: 135810
ISIN: INF277K019A3
First NAV in MFIC data: 29 Dec 2015
History: 10.8 years
Portfolio holdings: see the scheme's monthly portfolio disclosure on the fund house website
Schemes that behaved similarly correlation of monthly returns, last 5 years
| Scheme | Category | Correlation | 3Y CAGR |
|---|---|---|---|
| Mirae Asset Healthcare Fund | Sectoral/Thematic | 0.98 | 21.8% |
| Aditya Birla Sun Life Pharma and Healthcare Fund | Sectoral/Thematic | 0.97 | 20.1% |
| Nippon India Pharma Fund | Sectoral/Thematic | 0.97 | 17.6% |
| ICICI Prudential Healthcare Fund | Sectoral/Thematic | 0.97 | 21.1% |
| UTI - Healthcare Fund | Sectoral/Thematic | 0.97 | 22.5% |
| ITI Pharma and Healthcare Fund | Sectoral/Thematic | 0.97 | 18.9% |
Questions about Tata India Pharma & Healthcare Fund
- What is the latest NAV of Tata India Pharma & Healthcare Fund?
- The NAV of the Direct plan (growth option) was ₹38.0577 on 1 Oct 2026, as published by AMFI.
- Which category is Tata India Pharma & Healthcare Fund in?
- It is classified as Sectoral/Thematic in AMFI's daily NAV file; a Sectoral/Thematic scheme invests at least 80% in one sector or theme. MFIC compares it with 253 Sectoral/Thematic schemes (Direct plans).
- What returns has Tata India Pharma & Healthcare Fund delivered?
- Over one year the NAV changed by 7.9%. The 3-year CAGR is 18.3% (category median 13.0%) and the 5-year CAGR is 14.0% (category median 12.0%). Returns are after expenses and before tax. Past performance may or may not be sustained in future.
- How consistent have its 3-year returns been?
- Measuring a 3-year CAGR from every business day in its history, the median was 21.2%, the lowest was -3.4%, and 91% of 3-year periods ended with a gain. It was ahead of Nifty 500 (index-fund proxy) in 70% of those periods.
- What was the largest fall in Tata India Pharma & Healthcare Fund's NAV?
- The largest peak-to-trough fall in its available history was 19.8%; within the last five years it was 16.8% (category median 22.3%).
- How volatile is Tata India Pharma & Healthcare Fund?
- Its annualised standard deviation of monthly returns over the last 36 months is 16.5%, which is below the Sectoral/Thematic category median of 16.7%.
- What would a monthly SIP in Tata India Pharma & Healthcare Fund have grown to?
- A SIP of ₹10,000 on the first business day of each month for the last 5 years (60 instalments, ₹6,00,000 invested) would have been worth about ₹9,08,034 on 1 Oct 2026, an annualised return (XIRR) of 16.6%. This uses the Direct plan's NAVs, ignores taxes and exit loads, and past performance may or may not be sustained in future.
- What is the expense ratio (TER) of Tata India Pharma & Healthcare Fund?
- The total expense ratio of the Direct plan is 1.07% a year, as disclosed to AMFI (median of Sectoral/Thematic Direct plans: 1.15%). It is already deducted from the NAV, so every return shown is after expenses.
- How often has Tata India Pharma & Healthcare Fund beaten its category?
- At 68% of the 94 month-ends compared over the last 10 years, its 3-year return was above the median of Sectoral/Thematic schemes (Direct plans); it was in the top quarter at 49% of them. A typical scheme would show about 50%.
- Who manages Tata India Pharma & Healthcare Fund?
- According to its Scheme Summary Document, Tata India Pharma & Healthcare Fund is managed by Rajat Srivastava (since 16 Sep 2024).
- What is the exit load of Tata India Pharma & Healthcare Fund?
- As stated in its scheme documents: 0.25% of NAV if redeemed /switched out before 30 days from the date of allotment. Check the latest Scheme Information Document before investing, as loads can change.
- What is the minimum investment in Tata India Pharma & Healthcare Fund?
- The minimum application amount is ₹5,000. SIP details: SIP-- 100.00/100.00/100.00/100.00/100.00/100.00 ;STP --500.00/500.00/500.00/500.00 ;SWP --500.00/500.00/500.00/500.00.
- What is the difference between the Direct and Regular plans?
- Both plans hold the same portfolio; the Regular plan includes distribution costs in its expense ratio. Over one year the Direct plan's NAV changed by 7.9% and the Regular plan's by 6.4%. The Regular plan includes the services of a distributor.
Reviewing your own mutual fund portfolio?
Integrato's team can walk you through how your current schemes have behaved, using the same data shown here. Integrato is an AMFI-registered Mutual Fund Distributor.
Follow Tata India Pharma & Healthcare Fund by email
Every Monday: this scheme's NAV, 1-month and 1-year return beside its category median, 3-year CAGR and how far it is below its peak. Add more schemes from their pages or from your MFIC watchlist. Free; unsubscribe from any email.
Data & disclosure. Source: AMFI daily NAV file and historical NAVs via mfapi.in; calculations by MFIC, as of 1 Oct 2026. Category medians use Direct plans in the same AMFI category. Mutual fund investments are subject to market risks; read all scheme-related documents carefully. Past performance may or may not be sustained in future. This page is for research and education only and is not investment advice or a recommendation to buy, sell or hold any scheme. Integrato Financial Services Pvt. Ltd. is an AMFI-registered Mutual Fund Distributor (ARN-173155). Methodology.